Cosciens Biopharma's ROE % for the quarter that ended in Mar. 2026 was 449.12%. Cosciens Biopharma's PB Ratio for the quarter that ended in Mar. 2026 was 0.21.
Cosciens Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 2,138.67%.
Cosciens Biopharma ROE % Adjusted to Book Value Related Terms
Cosciens Biopharma ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma ROE % Adjusted to Book Value Chart
CSCIF vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Cosciens Biopharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 2,138.67% mean?
Cosciens Biopharma (CSCIF) has a ROE % Adjusted to Book Value of 2,138.67% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cosciens Biopharma and its competitors.
Is Cosciens Biopharma's ROE % Adjusted to Book Value too high?
Cosciens Biopharma's current ROE % Adjusted to Book Value is 2,138.67%. Overall, Cosciens Biopharma has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's ROE % Adjusted to Book Value compare to VRTX and REGN?
Cosciens Biopharma's ROE % Adjusted to Book Value of 2,138.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current ROE % Adjusted to Book Value is 2,138.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.35, compared to a current price of $1.99 — trading 15.3% below its estimated fair value. The current ROE % Adjusted to Book Value is 2,138.67%. Cosciens Biopharma's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current ROE % Adjusted to Book Value is 2,138.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $1.99 is trading 15.3% below its estimated GF Value™ of $2.35.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
ROE % Adjusted to Book Value: 2,138.67%
GF Value™: $2.35 vs. price of $1.99 (15.3% below fair value)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
62GF Score
Get the complete analysis for CSCIF
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
